All About Semaglutide, Ozempic, Wegovy & Rybelsus episode artwork

EPISODE · Jul 24, 2023 · 47 MIN

All About Semaglutide, Ozempic, Wegovy & Rybelsus

from Eat Move Think · host Ghost Bureau Content Services

Last year, Medcan director of weight management Dr. David Macklin predicted the diabetes medication semaglutide would be a game changer for those seeking help to lose weight. Now known by trade names like Ozempic, Wegovy and Rybelsus, today semaglutide is advertised on billboards and in TV commercials — and the hashtag has more than 330 million views on Tiktok. So we invited back Dr. Macklin to get his perspective on the medication, now that it's actually on the market and being used by hundreds of thousands of people across North America. Joined by Medcan CMO Dr. Peter Nord, Dr. Macklin explains semaglutide's benefits, side effects and costs — and describes what's different about Medcan's approach to weight management in the semaglutide era. DISCLOSURE In addition to his role at Medcan, Dr. Macklin helped to write the Canadian clinical guidelines for obesity. He also receives consulting fees, honoraria, and licensing fees from Novo Nordisk. Novo Nordisk is the manufacturer of semaglutide (trade name Ozempic). Check out the episode webpage for links and more info.

Episode metadata supplied by the publisher feed · Published Jul 24, 2023

Embed this episode

NOW PLAYING

All About Semaglutide, Ozempic, Wegovy & Rybelsus

0:00 47:28

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Eat Move Think?

This episode is 47 minutes long.

When was this Eat Move Think episode published?

This episode was published on July 24, 2023.

Can I download this Eat Move Think episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!